Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 37fludarabine phosphate 27Whole-Body Irradiation 26Cytarabine 26Mycophenolic Acid 22Methotrexate 20Filgrastim 19Peripheral Blood Stem Cell Transplantation 18Cyclosporine 18fludarabine 17venetoclax 15Busulfan 13Tacrolimus 12Granulocyte Colony-Stimulating Factor 12Cord Blood Stem Cell Transplantation 12Thiotepa 11Antilymphocyte Serum 11Melphalan 10Azacitidine 10Dexamethasone 9Cladribine 9Vincristine 8Specimen Handling 8Radiotherapy 8Mitoxantrone 8Methylprednisolone 8Idarubicin 7Cyclosporins 7Clofarabine 7Hydrocortisone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Biphenotypic, Acute × lirilumab × Clear all
NCT02399917 2019-09-24

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Terminated
36 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡